NEW YORK, July 11, 2019 /PRNewswire/ -- Neurotrope,
Inc. (Nasdaq: NTRP), a clinical- stage biopharmaceutical company
developing novel therapeutics for neurodegenerative diseases,
including Alzheimer's disease ("AD") is announcing that Dr.
Daniel L. Alkon, the Company's
President and CSO, will be honored among the recipients of the Cure
Coin Award, at the InvestAcure Cure Coin Awards Reception on
July 15, 2019 during the Alzheimer's
Association International Conference in Los Angeles.
"We are proud to honor Dr. Alkon for his work in the development
of Bryostatin, a natural compound showing promise in restoring
synaptic networks in the brain, preventing neuronal death, clearing
Tau and Amyloid buildup, and reversing Alzheimer's memory loss even
for patients with late-stage disease," said Max Tokarsky, Founder & CEO of InvestAcure,
PBC.
The award reception will bring together key stakeholders in the
battle against AD, Dementia and CTE to honor industry scientists
working to develop groundbreaking discoveries into effective
treatments. NFL 'super-agent' Leigh Steinberg and former Vice Chairman of the
NASDAQ David Weild IV are scheduled to host and keynote the
event. The event program will also feature a presentation by
InvestAcure, PBC Founder and CEO, Max Tokarsky, on their plans to drive
$1 billion in annual investment for
AD R&D until a cure is found.
The reception will be held at 7:00
p.m. at The Association on 110 E 6th Street in Downtown Los Angeles. InvestAcure welcomes
members of the press to request attendance at the event. The
event is expected to be at capacity, so please register as soon as
possible. For additional details and registration, please
visit the event page.
Neurotrope's Chief Executive Officer, Dr. Charles S. Ryan, will present the design of its
confirmatory Phase 2 double blind, placebo controlled clinical
trial of bryostatin-1 in the treatment of moderate to severe
Alzheimer's dementia. The study design will be presented as a
poster and Dr. Ryan will deliver an oral presentation. "We
are delighted that the work of Dr. Alkon will be recognized, and
look forward to the opportunity to present details of our
confirmatory trial that will inform the development of a pivotal
trial protocol for Bryostatin-1 in moderate-to-severe AD patients,"
said Dr. Ryan.
The poster presentation information is below.
Title: Replication Trial to Confirm Reversal of Cognitive
Decline with Bryostatin for Advanced Alzheimer's Patients in the
Absence of Memantine
(Poster
presentation Abstract #35676)
Developing Topics Session: P4-661
Poster Presentations, Wednesday, July 17, 2019,
9:30 AM - 4:15 PM Pacific time.
Oral Presentation by Dr. Charles
Ryan scheduled for 1:00 PM Pacific
time at the Los Angeles
Convention Center, South Hall GH.
About InvestAcure, PBC
InvestAcure, PBC is a finance company building an investment
platform to enable individuals who share a 'Common Need' to see
progress in developing a cure for Alzheimer's to automatically
round up purchases and invest the change in a portfolio of
companies working on effective treatments. The
company's 3-year plan is to reach 1.7+ million users,
investing $1 billion per annum to
develop scientific innovations from basic research into lifesaving
therapeutics.
Please visit www.investacure.com for further
information.
About Neurotrope
Neurotrope is at the forefront of developing a new approach to
combating AD and other neurodegenerative diseases. The Company's
world-class science offers the potential to realize a paradigm
shift to overcome one of today's most challenging clinical problems
— finding a way to slow or even prevent the progression of AD.
In addition to the Company's Phase 2 trial of Bryostatin-1 in
advanced AD, Neurotrope has also conducted preclinical studies of
Bryostatin-1 as a potential treatment for rare diseases and brain
injury, including Fragile X syndrome, multiple sclerosis, stroke,
Niemann-Pick Type C disease, Rett syndrome, and traumatic brain
injury. The U.S. Food and Drug Administration has granted Orphan
Drug Designation to Neurotrope for Bryostatin-1 as a treatment for
Fragile X. Bryostatin-1 has already undergone testing in more than
1,500 people in cancer studies, thus creating a large safety data
base that will further inform clinical trial designs.
Please visit www.neurotrope.com for further
information.
Forward-Looking Statements
Any statements contained in this press release that do not
describe historical facts may constitute forward-looking
statements. These forward-looking statements include statements
regarding the Phase 2 study and further studies, and continued
development of use of Bryostatin-1 for AD and other cognitive
diseases. Such forward-looking statements are subject to risks and
uncertainties and other influences, many of which the Company has
no control over. There can be no assurance that the clinical
program for Bryostatin-1 will be successful in demonstrating safety
and/or efficacy that we will not encounter problems or delays in
clinical development, or that Bryostatin-1 will ever receive
regulatory approval or be successfully commercialized. Actual
results and the timing of certain events and circumstances may
differ materially from those described by the forward-looking
statements as a result of these risks and uncertainties. Additional
factors that may influence or cause actual results to differ
materially from expected or desired results may include, without
limitation, the Company's inability to obtain adequate financing,
the significant length of time associated with drug development and
related insufficient cash flows and resulting illiquidity, the
Company's patent portfolio, the Company's inability to expand the
Company's business, significant government regulation of
pharmaceuticals and the healthcare industry, lack of product
diversification, availability of the Company's raw materials,
existing or increased competition, stock volatility and
illiquidity, and the Company's failure to implement the Company's
business plans or strategies. These and other factors are
identified and described in more detail in the Company's filings
with the Securities and Exchange Commission, including the
Company's Annual Report on Form 10-K for the year
ended December 31, 2018, and on Form 10-Q for the quarter
ended March 31, 2019. The Company does not undertake to update
these forward-looking statements.
Contact information:
Public Relations
Susan Roberts
sr@roberts-communications.com
202-779-0929
Investors and Media
Tom Caden
Vice President
CORE IR
516-222-2560
tomc@coreir.com
www.coreir.com
View original
content:http://www.prnewswire.com/news-releases/neurotrope-to-present-at-the-alzheimers-association-international-conference-neurotrope-president-and-chief-scientific-officer-dr-daniel-l-alkon-to-receive-cure-coin-award-design-of-confirmatory-phase-2-trial-to-be-presente-300883209.html
SOURCE Neurotrope, Inc.